Pioglitazone Is Associated with Lower Major Adverse Cardiovascular and Cerebrovascular Events than DPP4-Inhibitors in Diabetic Patients with End-Stage Renal Disease: A Taiwan Nationwide Cohort Study, 2006–2016

While pioglitazone reduces insulin resistance and hepatic gluconeogenesis effectively in patients with type 2 diabetes mellitus (T2DM), these benefits remained controversial in patients with end stage renal disease (ESRD). We compared major adverse cardiac cerebrovascular events (MACCEs) and mortali...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Min-Hao, Yang, Huang-Yu, Yen, Chieh-Li, Wu, Chao-Yi, Jenq, Chang-Chyi, Kuo, George, Peng, Wei-Sheng, Liu, Jia-Rou, Tian, Ya-Chung, Yang, Chih-Wei, Anderson, Gerard F., See, Lai-Chu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694655/
https://www.ncbi.nlm.nih.gov/pubmed/33172034
http://dx.doi.org/10.3390/jcm9113578

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694655/
https://www.ncbi.nlm.nih.gov/pubmed/33172034
http://dx.doi.org/10.3390/jcm9113578

Ejemplares similares